Julphar, BD to supply insulin pens in UAE

September 1, 2018

Julphar, a top pharmaceutical manufacturer in the Middle East and Africa, has signed an agreement with leading global medical technology company, BD (Becton, Dickinson and Company), to supply disposable insulin pens in the UAE.

Through this agreement, Julphar’s human insulin formulations including Jusline R, Jusline N and Jusline 30/70 will be available for administration through BD’s portfolio of BD Vystra disposable pens. In addition, the same device will be used for insulin analogues (insulin glargine and insulin lispro), which are still under development.

Jerome Carle, general manager of Julphar, said: “The global diabetes market is large and growing. Through our agreement with BD, we will be able to keep pace with the growth and further improve our position in this lucrative market placing us among the top three players in the world.”

“Many people in the UAE are suffering from what, in some cases, is a preventable condition. As a global leader in the manufacture of insulin, Julphar has a responsibility to not only raise awareness of the risk factors but to provide affordable, effective solutions that help diabetes sufferers live healthy, normal lives.

“An insulin pen offers more accuracy, convenience and confidence to diabetes sufferers and we look forward to launching these high-tech devices here in the very near future,” he added.

Insulin pens are small, disposable, lightweight plastic handheld devices containing prefilled insulin cartridges that are convenient and more versatile than some traditional methods for insulin injection.

More Stories